Amneal Pharmaceuticals, Inc. (AMRX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.0900 |
| Open | 2.1100 |
| Bid | 2.1200 x 3000 |
| Ask | 2.1800 x 4000 |
| Day's Range | 2.1050 - 2.2000 |
| 52 Week Range | 1.9500 - 4.9800 |
| Volume | |
| Avg. Volume | 1,213,727 |
| Market Cap | 328.616M |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | 3.61 |
| EPS (TTM) | 0.6100 |
| Earnings Date | Feb 28, 2023 - Mar 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Business Wire
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
BRIDGEWATER, N.J., January 31, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023.
- Investor's Business Daily
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.
- Bloomberg
US Releases Stockpiled Tamiflu Supplies Amid Cold, Flu Treatment Shortages
(Bloomberg) -- US health officials have released supplies of the flu drug Tamiflu from a national stockpile as shortages of cold and respiratory medications persist nationwide.Most Read from BloombergElon Musk Fan With 2,900% Gain Sees $1.5 Million Wiped AwayUS Inflation Cools Again, Putting Fed on Track to DownshiftT-Mobile Considers Buying Ryan Reynolds’s Mint MobileThe Document That Separates Biden and TrumpGoogle, Nvidia Express Concerns to FTC About Microsoft’s Activision DealMore than 52,0
